Abstract
With many controlled clinical trials and well documented case reports, therapy with intravenous immunoglobulins (IVIg) is now used as a major or adjuvant therapeutic modality in a great number of haematological diseases. Immune-mediated peripheral cytopenias with severe clinical complications may require instantaneous improvement and, generally, the response to high doses of IVIg is more rapid than that to corticosteroids. As a rule, the acute forms of idiopathic thrombocytopenic purpura (ITP) respond more consistently than the chronic forms, in which the response to IVIg is more transient. The immunopathogenic mechanisms leading to cytopenia crucially influence the response; for example, ITP due to HIV infection is more resistant to IVIg than acute ITP due to other viral infections or the purely idiopathic forms.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
